Branched-Chain Amino Acid Catabolism
Two Steps, One Regulatory Node
| Step | Enzyme | Compartment | Reversible |
|---|---|---|---|
| BCAA + α-ketoglutarate → branched-chain keto acid + glutamate | BCAT1 (cytosolic), BCAT2 (mitochondrial) | Both | Yes |
| Branched-chain keto acid → acyl-CoA | BCKDH complex (BCKDHA/B, DBT, DLD) | Mitochondrial | No |
| BCKDH inactivation | BCKDK (phosphorylation) | Mitochondrial | — |
| BCKDH activation | PPM1K (phosphatase) | Mitochondrial | — |
Important distinction. BCAT is reversible and BCKDH is not. This asymmetry means that the first step can run in either direction depending on the α-ketoglutarate and glutamate gradients, so a BCAA can donate its amino group without being catabolised for energy. Most BCAA measurements cannot distinguish transfer from catabolism.
Part 1 — The Three BCAAs Have Different Fates
| BCAA | Carbon fate | Anaplerotic or ketogenic |
|---|---|---|
| Leucine | Acetyl-CoA and acetoacetate | Ketogenic; no net anaplerosis |
| Isoleucine | Acetyl-CoA and propionyl-CoA | Both; propionyl-CoA is anaplerotic |
| Valine | Succinyl-CoA | Anaplerotic |
Caveat on treating BCAAs as a class. Leucine cannot replenish TCA intermediates; valine can. A study that measures "total BCAA" consumption and concludes that the TCA cycle was replenished has conflated three different carbon fates. Reporting the three separately is the minimum for a catabolism claim.
Part 2 — The Signalling Role
Leucine activates mTORC1 through Sestrin2 binding and through the lysosomal machinery described in the signalling literature. This is a signalling role that depends on leucine concentration, not on its catabolism.
| Role | Concentration dependence | Readout |
|---|---|---|
| mTORC1 activation | Sharp; sensitive around physiological leucine | p-S6K1, p-4E-BP1 |
| Nitrogen donation | Proportional to concentration | ¹⁵N transfer to glutamate and aspartate |
| Energy production | Requires BCKDH activity | ¹³C-leucine oxidation |
| Protein synthesis substrate | Proportional to demand | Incorporation |
Readout note. In culture, leucine is typically present at 0.4–0.8 mM, while plasma leucine is around 0.1–0.2 mM. The higher concentration means mTORC1 is often near-maximally activated at baseline, which compresses the dynamic range for a leucine experiment. A "leucine effect" measured in standard medium may be smaller than the same effect measured at a physiological concentration — or absent.
Part 3 — BCKDH Regulation
BCKDH activity is controlled by phosphorylation, and the balance between BCKDK and PPM1K sets it.
| Manipulation | BCKDH activity | Consequence |
|---|---|---|
| BCKDK overexpression | Low | BCAA and BCKA accumulate |
| PPM1K activation | High | BCAA clearance increases |
| High protein intake | Low (in some tissues) | BCAA remain elevated |
| Exercise or fasting | Tissue-dependent | Different directions in muscle and liver |
Important distinction. BCKDH regulation is tissue-specific and differs between species. Findings in mouse liver do not transfer automatically to human skeletal muscle, and the direction of the response to feeding differs between the two. A BCAA claim should name the tissue and the species.
Part 4 — Plasma BCAA and Insulin Resistance
Elevated circulating BCAAs are consistently associated with insulin resistance and predict type 2 diabetes in prospective cohorts. The causality question is separate and remains open.
| Interpretation | Supporting observation |
|---|---|
| BCAA elevation is a marker of impaired catabolism | BCKDH activity is reduced in insulin-resistant tissue |
| BCAA elevation contributes to insulin resistance | BCAA infusion and BCKDK manipulation affect glucose handling in models |
| Both reflect a common upstream defect | Changes in adipose tissue and liver metabolism precede both |
Caveat on the association. A prospective association with a hazard ratio is not a mechanism, and the mediation analyses published so far are consistent with several models. In cell culture, BCAA concentrations far above plasma make it difficult to test the physiological question at all.
Part 5 — Model Requirements and Recurring Failures
| Requirement | Why |
|---|---|
| Medium BCAA concentrations stated | They exceed plasma in most formulations |
| BCAA and BCKA measured together | The keto acids reveal catabolic flux |
| The three BCAAs reported separately | Carbon fates differ |
| Tissue and species stated | BCKDH regulation differs |
| Proliferation and mTORC1 measured | Signalling role competes with catabolism |
| Timepoint matched to the process | Transfer is fast; catabolism is slower |
Recurring failures:
- • Total BCAA reported, hiding the three different fates.
- • Nitrogen transfer reported as catabolism.
- • mTORC1 effects reported as metabolic effects, or the reverse.
- • Culture concentrations treated as physiological.
- • BCKDH activity inferred from BCAA concentration, which is also set by supply.
- • Mouse tissue findings transferred to human muscle.
- • BCKA not measured, so the irreversible step is unobserved.
Part 6 — Where This Article Connects
This is the BCAA article of the amino acid cluster, and it is the second major nitrogen-transfer system after glutamine. It connects to the glutaminolysis article through α-ketoglutarate, which BCAT consumes, and to the nucleotide article through the anaplerotic contribution of valine and isoleucine. The BCAA measurement article in this cluster covers the analytical detail.
If you need BCAA and BCKA measured with the three amino acids resolved, we can scope the analysis with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
BCAA concentrations, BCAT and BCKDH expression and their regulation vary with tissue, species and nutritional state. The patterns here are conditional.
BCAA concentration does not establish catabolic flux, and a prospective association with metabolic disease does not establish causality.
Scientific interpretation and experimental design
- • BCAT is reversible; BCKDH is not. Transfer is not catabolism.
- • Three BCAAs, three fates. Leucine cannot anaplerose.
- • Culture is supraphysiological. State the concentration.
- • Measure the keto acids.
- • Signalling and catabolism are different claims.
- • Species and tissue matter.
Selected references for further reading
- • Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. Nature Reviews Endocrinology. 2014;10:723–736.
- • Neinast M, Murashige D, Arany Z. Branched chain amino acids. Annual Review of Physiology. 2019;81:139–164.
- • White PJ, et al. The BCKDH kinase and phosphatase integrate BCAA and lipid metabolism via regulation of ATP-citrate lyase. Cell Metabolism. 2018;27:1281–1293.
- • Yoon MS. The emerging role of branched-chain amino acids in insulin resistance and metabolism. Nutrients. 2016;8:405.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »